Nykredit A S Acquires New Shares in Insmed, Inc. $INSM

Nykredit A S purchased a new position in shares of Insmed, Inc. (NASDAQ:INSM) in the 2nd quarter, Holdings Channel reports. The fund purchased 103,144 shares of the biopharmaceutical company’s stock, valued at approximately $10,997,000.

Several other large investors have also recently added to or reduced their stakes in INSM. B. Metzler seel. Sohn & Co. AG raised its position in shares of Insmed by 3.3% during the 2nd quarter. B. Metzler seel. Sohn & Co. AG now owns 40,521 shares of the biopharmaceutical company’s stock worth $4,320,000 after buying an additional 1,278 shares in the last quarter. Railway Pension Investments Ltd purchased a new position in shares of Insmed in the second quarter worth approximately $64,473,000. Headlands Technologies LLC lifted its holdings in shares of Insmed by 1,355.0% in the second quarter. Headlands Technologies LLC now owns 40,855 shares of the biopharmaceutical company’s stock valued at $4,356,000 after purchasing an additional 38,047 shares in the last quarter. Quantitative Investment Management LLC boosted its position in Insmed by 11.1% during the 2nd quarter. Quantitative Investment Management LLC now owns 15,894 shares of the biopharmaceutical company’s stock worth $1,694,000 after acquiring an additional 1,589 shares during the period. Finally, Wellington Management Group LLP grew its position in Insmed by 36.3% during the second quarter. Wellington Management Group LLP now owns 543,893 shares of the biopharmaceutical company’s stock valued at $57,990,000 after purchasing an additional 144,849 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. BMO Capital Markets initiated coverage on Insmed in a research report on Monday, July 20th. They issued an “outperform” rating and a $192.00 price target on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Insmed from $179.00 to $175.00 and set an “overweight” rating for the company in a research report on Monday, August 10th. Cantor Fitzgerald reiterated an “overweight” rating and set a $235.00 target price on shares of Insmed in a research report on Tuesday, July 28th. Mizuho set a $192.00 price objective on shares of Insmed in a research report on Tuesday, June 16th. Finally, Wells Fargo & Company lifted their target price on Insmed from $161.00 to $169.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $205.52.

Insmed Stock Down 0.3%

Insmed stock opened at $126.29 on Friday. The stock has a market capitalization of $27.58 billion, a PE ratio of -30.73 and a beta of 0.82. Insmed, Inc. has a twelve month low of $90.39 and a twelve month high of $212.75. The company has a 50 day moving average of $115.86 and a 200-day moving average of $125.22. The company has a quick ratio of 3.40, a current ratio of 3.72 and a debt-to-equity ratio of 0.74.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.61. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%.The business had revenue of $425.49 million for the quarter, compared to analyst estimates of $395.50 million. During the same quarter in the prior year, the company posted ($1.70) earnings per share. Insmed’s revenue was up 296.1% on a year-over-year basis. On average, equities research analysts anticipate that Insmed, Inc. will post -1.83 EPS for the current fiscal year.

Insider Buying and Selling

In other Insmed news, CEO William Lewis sold 10,699 shares of the firm’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $117.40, for a total transaction of $1,256,062.60. Following the transaction, the chief executive officer owned 259,058 shares in the company, valued at $30,413,409.20. This trade represents a 3.97% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Michael Smith sold 1,806 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $95.82, for a total transaction of $173,050.92. Following the sale, the insider owned 37,648 shares in the company, valued at $3,607,431.36. This represents a 4.58% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 273,753 shares of company stock valued at $35,604,764. Insiders own 2.10% of the company’s stock.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.